Optimizing AI models to predict esophageal squamous cell carcinoma risk by incorporating small datasets of soft palate images.

Journal: Scientific reports
Published Date:

Abstract

There is a currently an unmet need for non-invasive methods to predict the risk of esophageal squamous cell carcinoma (ESCC). Previously, we found that specific soft palate morphologies are strongly associated with increased ESCC risk. However, there is currently no artificial intelligence (AI) system that utilizes oral images for ESCC risk assessment. Here, we evaluated three AI models and three fine-tuning approaches with regard to their ESCC predictive power. Our dataset contained 539 cases, which were subdivided into 221 high-risk cases (2491 images) and 318 non-high-risk cases (2524 images). We used 480 cases (4295 images) for the training dataset, and the rest for validation. The Bilinear convolutional neural network (CNN) model (especially when pre-trained on fractal images) demonstrated diagnostic precision that was comparable to or better than other models for distinguishing between high-risk and non-high-risk groups. In addition, when tested with a small number of images containing soft palate data, the model showed high precision: the best AUC model had 0.91 (sensitivity 0.86, specificity 0.79). This study presents a significant advance in the development of an AI-based non-invasive screening tool for the identification of high-risk ESCC patients. The approach may be particularly suitable for institutes with limited medical imaging resources.

Authors

  • Kotaro Waki
    Department of Gastrointestinal Oncology, Osaka International Cancer Institute, 3-1-69 Otemae, Chuo-ku, Osaka, 541-8567, Japan.
  • Katsuya Nagaoka
    Department of Gastroenterology and Hepatology, Faculty of Life Sciences, Kumamoto University, 1-1-1 Honjo, Chuo-ku, Kumamoto, Kumamoto, 860-8556, Japan.
  • Keishi Okubo
    Faculty of Advanced Science and Technology, Kumamoto University, Kumamoto, Japan.
  • Masato Kiyama
    Faculty of Advanced Science and Technology, Kumamoto University, 2-39-1 Kurokami, Kumamoto 860-8555, Japan. Electronic address: masato@cs.kumamoto-u.ac.jp.
  • Ryosuke Gushima
    Department of Gastroenterology and Hepatology, Faculty of Life Sciences, Kumamoto University, 1-1-1 Honjo, Chuo-ku, Kumamoto, Kumamoto, 860-8556, Japan.
  • Kento Ohno
    Department of Gastroenterology and Hepatology, Faculty of Life Sciences, Kumamoto University, 1-1-1 Honjo, Chuo-ku, Kumamoto, Kumamoto, 860-8556, Japan.
  • Munenori Honda
    Department of Gastroenterology and Hepatology, Faculty of Life Sciences, Kumamoto University, 1-1-1 Honjo, Chuo-ku, Kumamoto, Kumamoto, 860-8556, Japan.
  • Akira Yamasaki
    Division of Medical Oncology and Molecular Respirology, Department of Multidisciplinary Internal Medicine, School of Medicine, Tottori University Faculty of Medicine, Tottori, Japan.
  • Kenshi Matsuno
    Department of Gastrointestinal Oncology Osaka International Cancer Institute Osaka Japan.
  • Yoki Furuta
    Department of Gastroenterology and Hepatology, Faculty of Life Sciences, Kumamoto University, 1-1-1 Honjo, Chuo-ku, Kumamoto, Kumamoto, 860-8556, Japan.
  • Hideaki Miyamoto
    Department of Gastroenterology and Hepatology, Faculty of Life Sciences, Kumamoto University, 1-1-1 Honjo, Chuo-ku, Kumamoto, Kumamoto, 860-8556, Japan.
  • Hideaki Naoe
    Department of Gastroenterology and Hepatology, Faculty of Life Sciences, Kumamoto University, 1-1-1 Honjo, Chuo-ku, Kumamoto, Kumamoto, 860-8556, Japan.
  • Motoki Amagasaki
    Faculty of Advanced Science and Technology, Kumamoto University, 2-39-1 Kurokami, Kumamoto 860-8555, Japan. Electronic address: amagasaki@cs.kumamoto-u.ac.jp.
  • Yasuhito Tanaka
    Department of Gastroenterology and Hepatology, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan.